About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker AVIR · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 12, 2026A Study of GSM-779690T in Healthy Adult Participants
NCT07690228 · Healthy Adult Participants, Alzheimer Disease
GSM-779690T, Placebo
AVIR
Acta Pharmaceuticals
Phase 1Recruiting
was not yet recruiting
72Nov 2027Registry ↗
Oct 29, 2026C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV
NCT06868264 · HEPATITIS C VIRUS CHRONIC INFECTION
Bemnifosbuvir-Ruzasvir (BEM/RZR), Sofosbuvir-Velpatasvir (S…
AVIR
Atea Pharmaceuticals, Inc.
Phase 3Completed
was active, not recruiting
940Jun 18, 2026Registry ↗
Oct 28, 2026Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Metha…
NCT07314346 · Healthy Volunteer Study
Buprenorphine/Naloxone + BEM/RZR, Methadone +BEM/RZR
AVIR
Atea Pharmaceuticals, Inc.
Phase 1Completed30Jul 23, 2026Registry ↗
Jul 31, 2026Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Imp…
NCT06911320 · Healthy Volunteer Study, Hepatic Impairment
Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combinat…
AVIR
Atea Pharmaceuticals, Inc.
Phase 1Completed28Apr 30, 2026Registry ↗
Jul 27, 2026Study of AT-587 in Healthy Subjects
NCT07728487 · Hepatitis E
AT-587, Placebo
AVIR
Atea Pharmaceuticals, Inc.
Phase 1Recruiting62Dec 2026Registry ↗
Jun 29, 2026C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV
NCT07037277 · HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic
Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir
AVIR
Atea Pharmaceuticals, Inc.
Phase 3Active, not recruiting880Dec 2026Registry ↗
Apr 13, 2026Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestre…
NCT07272889 · Healthy Volunteer Study
Ethinyl Estradioll/Levonorgestrel (EE/LNG), Bemnifosbuvir/R…
AVIR
Atea Pharmaceuticals, Inc.
Phase 1Completed24Feb 17, 2026Registry ↗
Jan 7, 2026A Clinical Trial to Study Single- and Multiple- Doses of GSM-779690T in Healthy Participants
NCT07155980 · Healthy Adult Participants
GSM-779690T, Placebo
AVIR
Acta Pharmaceuticals
Phase 1Withdrawn0Jul 11, 2026Registry ↗
Oct 21, 2025A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic H…
NCT05904470 · Chronic Hepatitis C Virus, Hepatitis C, Chronic
Bemnifosbuvir, Ruzasvir
AVIR
Atea Pharmaceuticals, Inc.
Phase 2Completed275Dec 9, 2024Registry ↗
Aug 29, 2025Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir
NCT07007806 · Healthy Volunteer Study
Treatment A-Bemnifosbuvir/Ruzasvir FDC administered fasting…
AVIR
Atea Pharmaceuticals, Inc.
Phase 1Completed20Jun 28, 2025Registry ↗
Aug 29, 2025Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and Rosuvastatin
NCT06921941 · Healthy Volunteer Study
Digoxin vs Digoxin + BEM/RZR vs Digoxin + 2h BEM/RZR, Rosuv…
AVIR
Atea Pharmaceuticals, Inc.
Phase 1Completed38Jul 2, 2025Registry ↗
Jun 13, 2025SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19
NCT05629962 · Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2…
Bemnifosbuvir (BEM), Placebo
AVIR
Atea Pharmaceuticals, Inc.
Phase 3Completed2,285Apr 25, 2024Registry ↗
Sep 19, 2024Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir
NCT06204679 · Healthy Volunteer Study
Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting condit…
AVIR
Atea Pharmaceuticals, Inc.
Phase 1Completed42Aug 25, 2024Registry ↗
Jul 31, 2024Drug-drug Interaction Study of Biktarvy and Bemnifosbuvir/Ruzasvir
NCT06356194 · Healthy Volunteer Study
Cohort 1: Days 1-7 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-ad…
AVIR
Atea Pharmaceuticals, Inc.
Phase 1Completed28May 30, 2024Registry ↗
Jul 31, 2024Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function
NCT05724693 · Healthy Volunteer, Hepatic Impairment
Bemnifosbuvir (BEM)
AVIR
Atea Pharmaceuticals, Inc.
Phase 1Completed39Apr 23, 2024Registry ↗
Jul 31, 2024Study of AT-527 in Subjects With Normal and Impaired Renal Function
NCT05618314 · Healthy Volunteer, Renal Impairment
AT-527, AT-527
AVIR
Atea Pharmaceuticals, Inc.
Phase 1Completed36Jun 15, 2024Registry ↗
Mar 5, 2024Study of AT-752 in Patients With Dengue Infection
NCT05466240 · Dengue Fever
AT-752, Placebo
AVIR
Atea Pharmaceuticals, Inc.
Phase 2Terminated21Jan 19, 2023Registry ↗
Jun 15, 2023The Study of Bemnifosbuvir in Healthy Japanese Subjects
NCT05905497 · Healthy Volunteer Study
Bemnifosbuvir (BEM)
AVIR
Atea Pharmaceuticals, Inc.
Phase 1Completed14May 19, 2023Registry ↗
Jun 15, 2023Study of Bemnifosbuvir on Cardiac Repolarization in Healthy Subjects
NCT05905484 · Healthy Volunteer Study
Bemnifosbuvir (BEM), Placebo
AVIR
Atea Pharmaceuticals, Inc.
Phase 1Completed35May 31, 2023Registry ↗
Jun 1, 2023Drug-drug Interaction Study of Ruzasvir and Bemnifosbuvir
NCT05731843 · Healthy Volunteer Study
Cohort 1 BEM + Ruzasvir, Cohort 2 Ruzasvir + BEM
AVIR
Atea Pharmaceuticals, Inc.
Phase 1Completed32Mar 15, 2023Registry ↗
Apr 21, 2023Study of AT-752 in Healthy Subjects in a Dengue Human Challenge Model
NCT05366439 · Dengue
AT-752, Placebo Comparator
AVIR
Atea Pharmaceuticals, Inc.
Phase 1Terminated5Mar 16, 2023Registry ↗
Mar 9, 2023Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) in a Hospita…
NCT04396106 · COVID-19
AT-527, Placebo
AVIR
Atea Pharmaceuticals, Inc.
Phase 2Terminated83Jan 10, 2022Registry ↗
Oct 18, 2022Study of AT-527 in Healthy Subjects Under Fasting Conditions or With a Meal
NCT05256732 · Healthy Volunteer Study
AT-527 fasted, Placebo Comparator fasted
AVIR
Atea Pharmaceuticals, Inc.
Phase 1Completed136Aug 23, 2022Registry ↗
Oct 17, 2022Study of AT-752 in Healthy Subjects
NCT04722627 · Dengue
AT-752, Placebo
AVIR
Atea Pharmaceuticals, Inc.
Phase 1Completed65Nov 14, 2021Registry ↗
Jun 8, 2022Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects
NCT04309734 · Hepatitis C, Hepatitis C, Chronic
AT-777, Placebo
AVIR
Atea Pharmaceuticals, Inc.
Phase 1/2Withdrawn0Jun 2022Registry ↗
Feb 28, 2022Drug-drug Interaction Study of Digoxin and AT-527 (R07496998)
NCT05137626 · Healthy Volunteers Study
AT-527 + digoxin, AT-527 + digoxin
AVIR
Atea Pharmaceuticals, Inc.
Phase 1Completed29Dec 12, 2021Registry ↗
Feb 25, 2022Drug-drug Interaction Study of Rosuvastatin and AT-527 (R07496998)
NCT05154123 · Healthy Volunteer Study
Drug: AT-527 + rosuvastatin, AT-527 + rosuvastatin
AVIR
Atea Pharmaceuticals, Inc.
Phase 1Completed29Dec 23, 2021Registry ↗
Feb 25, 2022Mass Balance Study of AT-527 in Healthy Adult Male Subjects (R07496998)
NCT05004415 · Healthy Volunteer Study
AT-527 (R07496998)
AVIR
Atea Pharmaceuticals, Inc.
Phase 1Completed6Aug 12, 2021Registry ↗
Feb 25, 2022Bronchopulmonary PK of AT-527 (R07496998)
NCT04877769 · Healthy Volunteer Study
AT-527
AVIR
Atea Pharmaceuticals, Inc.
Phase 1Completed24Aug 31, 2021Registry ↗
Feb 25, 2022Study of AT-527 in Healthy Subjects (R07496998)
NCT04711187 · Healthy Volunteer Study
AT-527 Formulation 1, Placebo Comparator
AVIR
Atea Pharmaceuticals, Inc.
Phase 1Completed81Sep 15, 2021Registry ↗
Aug 2, 2021Effect of Cyclosporine on the Pharmacokinetics (PK) of AT-527 (R07496998)
NCT04849299 · Healthy Volunteer Study
AT-527 550 mg + cyclosporine, AT-527 550 mg + cyclosporine
AVIR
Atea Pharmaceuticals, Inc.
Phase 1Completed24May 10, 2021Registry ↗
Jul 29, 2021Drug-drug Interaction Study of Midazolam and AT-527 (R07496998)
NCT04865445 · Healthy Volunteer Study
AT-527 550 mg + midazolam, AT-527 550 mg + midazolam
AVIR
Atea Pharmaceuticals, Inc.
Phase 1Completed24May 15, 2021Registry ↗
Jul 29, 2021Effect of Carbamazepine on the Pharmacokinetics (PK) of AT-527
NCT04784000 · Healthy Volunteer Study
Period 1: AT-527 550 mg, Period 2: carbamazepine
AVIR
Atea Pharmaceuticals, Inc.
Phase 1Completed20Apr 10, 2021Registry ↗
May 4, 2020Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection
NCT04019717 · Hepatitis C, Hepatitis C, Chronic
AT-527, Daclatasvir
AVIR
Atea Pharmaceuticals, Inc.
Phase 2Completed10Jan 29, 2020Registry ↗
Feb 18, 2020Study of AT-527 in Healthy and HCV-Infected Subjects
NCT03219957 · Chronic Hepatitis C, Hepatitis C
AT-527, Placebo Comparator
AVIR
Atea Pharmaceuticals, Inc.
Phase 1Completed88Jun 20, 2018Registry ↗

35 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:08 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances